Paysign price target raised to $7 from $6 at Lake Street

Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $7 from $6 and keeps a Buy rating on the shares. Paysign’s 261% year-over-year pharma growth was greater-than-expected and the company “remains in the early innings of an earnings inflection driven by pharma’s rapid program growth,” the analyst tells investors in a post-earnings note.